Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Explore this paper's citation graph
Summary
Using a dosing schedule of cyclophosphamide that provided more sustained apoptosis of endothelial cells within the vascular bed of a tumor, it is shown that a chemotherapeutic agent can more effectively control tumor growth in mice, regardless of whether the tumor cells are drug resistant.
- Type
- article
- Published
- 2000-04-01
- Cited by
- 1,660
- References
- 62
- OpenAlex
- https://openalex.org/W1943173994
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:9224199
Keywords
Lewis lung carcinoma, Cyclophosphamide, Medicine, Angiogenesis, Chemotherapy
References
- Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism.
- EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.
- Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
- Antiangiogenesis is produced by nontoxic doses of vinblastine.
- Investigation of the activity of cytoxan against leukemia L1210 in mice.
- Salvage weekly paclitaxel in recurrent ovarian cancer.
- Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay.
- UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
- Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes.
- Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
- Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia.
- Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
- Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.
- Cell kinetic-directed sequential chemotherapy with cyclophosphamide and adriamycin in T1699 mammary tumors.
- Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4.
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.
- Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
- Tumor angiogenesis: therapeutic implications.
- Paclitaxel (Taxol): An Inhibitor of Angiogenesis in a Highly Vascularized Transgenic Breast Cancer
- Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute.
Cited by
- A Model of Vascular Tumor Response to Chemotherapy Combined with Anti-Angiogenic Therapy
- Vascular density and bone marrow fibrosis in childhood acute lymphoblastic leukemia
- Compounds in clinical Phase III and beyond.
- Effective therapy of a vascular tumor of infancy with vincristine.
- Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
- A role for survivin in chemoresistance of endothelial cells mediated by VEGF
- Targeting Angiogenic Processes by Combination Low-Dose Paclitaxel and Radiation Therapy
- Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting.
- Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity.
- Response to vinorelbine and low‐dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor
- Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas
- EPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation
- Development of a Cancer Vaccine Targeting Tumor Blood Vessels
- Investigation of the relationship of nonlinear backscattered ultrasound intensity with microbubble concentration at low MI.
- Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
- Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
- Inhibition of tumors cell growth in osteosarcoma-bearing SD rats through a combination of conventional and metronomic scheduling of neoadjuvant chemotherapy
- Metronomic chemotherapy in veterinary patients with cancer: rethinking the targets and strategies of chemotherapy.
- Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?
- Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma
Related papers
- Mechanism study of thalidomide regulating angiogenesis in Lewis lung cancr model
- Metronomic Chemotherapy-a Novel Treatment Choice for Metastatic Breast Cancer
- Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy.
- Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.
- Suppression of tumor malignancy by NK4, a four-kringle fragment of HGF, that inhibits invasion-metastasis and angiogenesis
- PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells.
- Antiangiogenic experiment of docetaxel chemotherapy in lung cancer-bearing murine model
- Angiogenic inhibition for the treatment of head and neck cancer.